Press Releases
Oxford, November 30, 2020 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announces the formation of
Read MoreOxford, UK, 24 September 2020 – Professor David Kerr, The Chief Medical Officer of Celleron Therapeutics, the UK-based clinical stage
Read MoreOxford, 12th August 2020 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the signing
Read MoreOxford, UK / Sichuan, China, 15 May 2020 Today marks the launch of the University of Oxford-Sichuan University Huaxi Joint
Read MoreOxford, UK, 2nd March 2020 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced that
Read MoreLack of colitis side effect with CXD101 and nivolumab combination therapy in CAROSELL Phase II clinical trial of MSS CRC
Read MoreOxford, UK,21 October 2019 – Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients, today
Read MoreOxford, UK, 30th September 2019 – Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients,
Read MoreOxford, UK, 6 August 2019 – Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients,
Read MoreOxford, UK, 17 Jun 2019 – Celleron Therapeutics, a UK-based company developing personalised medicines for cancer patients, announced today approval
Read More